A staged phase 1 study of the treatment of malignant glioma with G207, a genetically engineered HSV-1 [herpes simplex 1], followed by radiation therapy

Trial Profile

A staged phase 1 study of the treatment of malignant glioma with G207, a genetically engineered HSV-1 [herpes simplex 1], followed by radiation therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2013

At a glance

  • Drugs G 207 (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top